I am a
Home I AM A Search Login

Papers of the Week


Papers: 13 Apr 2019 - 19 Apr 2019


Human Studies, Pharmacology/Drug Development

PAIN TYPE:
Migraine/Headache


2019 Jun


Cephalalgia


39


7

Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.

Authors

Goadsby PJ, Paemeleire K, Broessner G, Brandes J, Klatt J, Zhang F, Picard H, Lenz R, Mikol DD
Cephalalgia. 2019 Jun; 39(7):817-826.
PMID: 30982348.

Abstract

Erenumab was effective and well tolerated in a pivotal clinical trial of episodic migraine that included subjects both naïve to, and those who had failed, previous preventives. Here we evaluated the efficacy and safety of erenumab (70 mg or 140 mg) versus placebo in the subgroup of patients who had previously failed preventive treatment(s): ≥1 or ≥2 prior failed migraine preventive categories, and in patients who had never failed.